智通财经APP获悉,周二,燃石医学(BNR.US)涨24%,报3.61美元,最新市值达3703.4万美元。据悉,燃石医学专注于肿瘤患者基因检测,覆盖靶向治疗、免疫治疗等场景,提供多基因平行检测服务,助力临床用药决策。该公司与迪哲医药合作开发的EGFR exon20ins伴随诊断试剂盒于2024年10月获批,成为中国首个基于NGS技术的肺癌伴随诊断产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.